CRISPR THERAPEUTICS AG (CRSP:NASDAQ)
$49.01 -0.38 (-0.7694%)
Analysed CRISPR THERAPEUTICS AG (CRSP:NASDAQ) News Sources
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.
18-10-2026
fool.com
Where Will CRISPR Therapeutics Stock Be in 2030?
18-10-2026
fool.com
CRISPR Therapeutics Announces Chief Financial Officer Transition
19-10-2026
yahoo.com
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
21-10-2026
yahoo.com
CRISPR Therapeutics AG (CRSP) Stock Moves -1.21%: What You Should Know
22-10-2026
yahoo.com
The Outlook of CRISPR Therapeutics Stock Does Not Look Strong After Its CFO Resigns
23-10-2026
barchart.com
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
23-10-2026
yahoo.com
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More
24-10-2026
fool.com
CRISPR Therapeutics (CRSP) Promotes Andrew Silver To CFO As Raju Prasad Resigns
25-10-2026
yahoo.com
Learn Why The Bull Case For CRISPR Therapeutics Stock Could Change Following CFO Change
25-10-2026
yahoo.com
What is the current price of CRISPR THERAPEUTICS AG (CRSP:NASDAQ)?
The current price of CRISPR THERAPEUTICS AG (CRSP:NASDAQ) is $49.01.
CRISPR THERAPEUTICS AG (CRSP:NASDAQ) absolute price change since previous trading day?
The absolute price change of CRISPR THERAPEUTICS AG (CRSP:NASDAQ) since the previous trading day is $-0.38.
CRISPR THERAPEUTICS AG (CRSP:NASDAQ) percentage price change since previous trading day?
The percentage price change of CRISPR THERAPEUTICS AG (CRSP:NASDAQ) since the previous trading day is -0.7694%.
What is the most recent average sentiment score for CRISPR THERAPEUTICS AG (CRSP:NASDAQ)?
The most recent average sentiment score for CRISPR THERAPEUTICS AG (CRSP:NASDAQ) is 70 out of 100.
What is the most recent average sentiment for CRISPR THERAPEUTICS AG (CRSP:NASDAQ)?
The most recent sentiment for CRISPR THERAPEUTICS AG (CRSP:NASDAQ) is .
SEC-8K** Filing Available For CRISPR THERAPEUTICS AG (CRSP:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.